about
Hydrogen sulfide as a mediator of human corpus cavernosum smooth-muscle relaxationPatterns of treatment with PDE5 inhibitors in the clinical practice in Italy: longitudinal data from the Erectile Dysfunction Observational Study.Endogenous urotensin II selectively modulates erectile function through eNOSInvolvement of beta 3-adrenergic receptor activation via cyclic GMP- but not NO-dependent mechanisms in human corpus cavernosum function.Pharmacology of erectile dysfunction in man.The detrusor muscle: an innocent victim of bladder outlet obstruction.Androgens and morphologic remodeling at penile and cardiovascular levels: a common piece in complicated puzzles?Tadalafil and vardenafil vs sildenafil: a review of patient-preference studies.A new era in the treatment of erectile dysfunction: chronic phosphodiesterase type 5 inhibition.Radical perineal prostatectomy versus radical retropubic prostatectomy after previous prostate surgery: surgical and functional outcomes.Sexually Transmitted Disease and Male Infertility: A Systematic Review.Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient.BPH/LUTS and ED: common pharmacological pathways for a common treatment.Erectile dysfunction in patients with chronic viral hepatitis: a systematic review of the literature.The impact of non-urologic drugs on sexual function in men.Urothelium muscarinic activation phosphorylates CBS(Ser227) via cGMP/PKG pathway causing human bladder relaxation through H2S production.A survey on the experience of 136 Italian urologists in the treatment of erectile dysfunction with PDE5 inhibitors and recommendations for the use of Avanafil in the clinical practice.Versatility of the ventral approach in bulbar urethroplasty using dorsal, ventral or dorsal plus ventral oral grafts.Differential in vivo urodynamic measurement in a single thin catheter based on two optical fiber pressure sensors.Demographic and comorbidity profile of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a real-life clinical setting: Are 5-alpha-reductase inhibitor consumers different?Transperineal repair of a persistent rectourethral fistula using a porcine dermal graft.Aesthetic neo-glans reconstruction after penis-sparing surgery for benign, premalignant or malignant penile lesions.Simplification of classification and surgical expertise in the delayed treatment of traumatic posterior urethral injuries.A new therapeutic approach to erectile dysfunction: urotensin-II receptor high affinity agonist ligands.An ex vivo standardized assay to measure human platelet cGMP.Sildenafil effect on the human bladder involves the L-cysteine/hydrogen sulfide pathway: a novel mechanism of action of phosphodiesterase type 5 inhibitors.Platelet cyclic guanosine monophosphate as a biomarker of phosphodiesterase type 5 inhibitor efficacy in the treatment of erectile dysfunction: a randomized placebo-controlled study.A new biopsy technique to investigate Peyronie's disease associated histologic alterations: results with two different forms of therapy.Dapoxetine treatment in patients with lifelong premature ejaculation: the reasons of a "Waterloo".Open versus laparoscopic partial nephrectomy for clinical T1a renal masses: a matched-pair comparison of 280 patients with TRIFECTA outcomes (RECORd Project).Histological alterations in cavernous tissue after radical prostatectomy.Periprostatic nerve block (PNB) alone vs PNB combined with an anaesthetic-myorelaxant agent cream for prostate biopsy: a prospective, randomized double-arm study.Medical expulsive therapy for distal ureteric stones: tamsulosin versus silodosin.Renal transplantation does not improve erectile function in hemodialysed patients.Sphingosine 1-phosphate induces endothelial nitric-oxide synthase activation through phosphorylation in human corpus cavernosum.Flexible-dose vardenafil in a community-based population of men affected by erectile dysfunction: a 12-week open-label, multicenter trial.Editorial Comment on "Evaluation of the Treatment of Congenital Penile Curvature including Psycho-Sexual Assessment".Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie's disease and erectile dysfunction: results from a prospective randomized trial.A report from a single institute's 14-year experience in treatment of male-to-female transsexuals.Correlation between detrusor collagen content and urinary symptoms in patients with prostatic obstruction.
P50
Q24656291-F09328AB-6A6E-426F-9153-5A432A8FEF92Q33495987-22DEAE60-B95C-47D5-BB51-065F214DA792Q34154714-6C1963CC-58B6-40C1-8AE5-0B9190CAB43CQ34983511-430D0D2C-F4AA-4A27-B7F6-DEF5E160EA40Q36380335-E115E6F9-B4B9-4E34-8E99-EAB9D0195361Q36595583-AF1C41C2-2A8F-46BB-ABE7-CA08BBB85D29Q37369488-B2930D19-A811-44B0-B7B9-DACED84002C4Q37372803-F4A7DEFB-F749-49DF-8B0C-FD8C6CF71499Q37765650-DFB67491-E4E6-4F9E-8C19-EAEFD6FA1306Q37813371-EDEF017F-77BB-464F-8B0F-0C57D0305FEDQ37833779-E9BB9222-679F-4F2A-9A48-FB34C3DD094CQ37945315-188DCE00-2E79-48CC-AB03-AFEB26D4F1E4Q38123213-8B2CB90A-1800-4E0C-8E5B-F1392CA6BE37Q38161511-D16EF65A-BF6C-4CD1-BF0E-1DB9683A4007Q38202475-35A645C3-9873-48E8-976A-9446FD2D584AQ38752696-5AC2A0C3-778C-4FBC-96C5-E94829DD8437Q39633189-ECC55973-1635-4FD9-8F48-FCDCBF6E0A45Q41034941-DBBA4276-4008-4782-81AE-31CB31576D40Q41256343-70A92131-D865-4D9C-9554-E8B18DFD9BC3Q41709993-B43BF0B2-9011-4E1E-881B-8FF0799BDD1EQ41823049-46988A9F-2342-4E51-8DBA-53BB060E6319Q41872859-A5792C59-EF90-478A-BE62-3B9A67C3E63EQ42053770-7FF56EC5-8DBE-4ACD-8CD9-FF6AB9C2D0F3Q42139903-5F048004-1A03-4299-8F67-7A6C5F383CD4Q42492332-35565C70-3A56-4C20-A7A1-BDE72226838CQ42510309-D4FB76B0-D726-4F42-902F-DFBC28672BC5Q43271130-831A0513-0443-433B-8487-0BA7C9C4B33AQ44138028-A036F91F-FD25-470F-96CA-A333EC670415Q44844480-8A1F4CCA-7BE7-4D90-9E9E-5E3E7EDA7FF8Q45849222-752CF939-F9EC-41A2-9E9F-A8D3EAB8DD08Q45968091-739B4720-7EC9-4473-9E50-1FD6103B27A4Q46236371-9D1397AD-E8EE-4556-A4B6-FA08E3F2FC61Q46244356-6964897A-B21D-42B6-84F5-11BD09B499A3Q46332174-188D9393-E4FD-4EE5-B763-7E18E8CF08AFQ46761480-D617BCE3-7E6D-4D51-966C-9C95F8D01911Q46901016-0C442ADF-5837-408F-9A45-B01A789C1216Q47992200-B09CB5B7-E30B-4705-8E44-EF12E31F491DQ48545304-0A64F9DE-F134-4744-8B44-C974BD1D1AFEQ51625371-DE20CB0C-8A72-4065-9814-E9DE9F677E7AQ51989504-A9F09189-D177-42DE-BA8E-9F6A52F774E4
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ferdinando Fusco
@ast
Ferdinando Fusco
@en
Ferdinando Fusco
@es
Ferdinando Fusco
@nl
Ferdinando Fusco
@sl
type
label
Ferdinando Fusco
@ast
Ferdinando Fusco
@en
Ferdinando Fusco
@es
Ferdinando Fusco
@nl
Ferdinando Fusco
@sl
prefLabel
Ferdinando Fusco
@ast
Ferdinando Fusco
@en
Ferdinando Fusco
@es
Ferdinando Fusco
@nl
Ferdinando Fusco
@sl
P106
P1153
7006608236
P21
P31
P496
0000-0002-5158-5526